Agomab director reports 32,700-share option holding

Agomab Therapeutics NV director Verduyn-van Weegen Felice Isabel reported an initial stock option holding for 32,700 common shares.

Rhea-AI Filing Summary

Agomab Therapeutics NV director Verduyn-van Weegen Felice Isabel reported an initial stock option holding for 32,700 common shares. The option has an exercise price of $14.2600 per share and expires on January 15, 2036.

According to the filing, 33% of the underlying shares vest on February 9, 2027, with the remainder vesting in 24 equal monthly installments, subject to continued service. The common shares may be represented by American Depositary Shares, each currently representing one common share.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Verduyn-van Weegen Felice Isabel

Role Director

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy)	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 32,700 contracts (Direct)

Footnotes (3)

1. F1. 33% of the shares underlying this option shall vest on February 9, 2027 with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
2. F2. The common shares may be represented by American Depositary Shares, each of which currently represents one common share.
3. F3. The exercise prices are reported in U.S. dollars and reflect the conversion from EUR to USD at an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock options did Verduyn-van Weegen Felice Isabel report in Agomab Therapeutics (AGMB) Form 3?

The director reported a stock option over 32,700 Agomab common shares. The option carries an exercise price of $14.2600 per share and expires on January 15, 2036, representing a long-dated equity incentive position.

How do the Agomab Therapeutics (AGMB) stock options for Verduyn-van Weegen vest?

The option vests 33% of its underlying shares on February 9, 2027. The remaining shares vest in twenty-four equal monthly installments thereafter, conditioned on the director’s continued service on each relevant vesting date.

What is the exercise price and currency basis of the Agomab (AGMB) director’s stock options?

The reported exercise price is $14.2600 per share, stated in U.S. dollars. It reflects conversion from euros using an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026, according to the filing footnote.

When do the Agomab Therapeutics (AGMB) director’s stock options expire?

The stock option position expires on January 15, 2036. This long expiration horizon gives the director a multi-year window to exercise the right to buy up to 32,700 common shares at the fixed exercise price, once vested.

How are Agomab Therapeutics (AGMB) common shares represented for the reported stock options?

The filing notes that Agomab common shares may be represented by American Depositary Shares. Each American Depositary Share currently represents one common share, aligning the option’s underlying security with the ADS structure described.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 04:01 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Verduyn-van Weegen Felice Isabel

(Last) (First) (Middle)

AGOMAB THERAPEUTICS NV

POSTHOFLEI 1/6

(Street)

ANTWERPEN 2600

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Agomab Therapeutics NV [ AGMB ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	01/15/2036	Common shares(2)	32,700	$14.26(3)	D

Explanation of Responses:

1. 33% of the shares underlying this option shall vest on February 9, 2027 with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

2. The common shares may be represented by American Depositary Shares, each of which currently represents one common share.

3. The exercise prices are reported in U.S. dollars and reflect the conversion from EUR to USD at an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Ellen Lefever, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)